Classification of Morphea (Localized Scleroderma)

Lynne Peterson, Audrey M. Nelson, W. P.Daniel Su

Research output: Contribution to journalArticle

333 Citations (Scopus)

Abstract

To classify and describe morphea (localized scleroderma). A review of morphea and its subtypes is presented. The current classification of morphea is incomplete and confusing. As knowledge of the spectrum of disease continues to evolve, the controversy and confusing nature of its multiple subtypes present a challenge for the physician who encounters a patient with this condition. Thus, we propose that morphea be classified into the following five groups: plaque, generalized, bullous, linear, and deep. This classification, based on clinical morphologic findings, will simplify the diagnostic and therapeutic approach. Morphea represents a wide variety of clinical entities that seem to be on the opposite end of the scleroderma spectrum from systemic sclerosis. The cutaneous lesions eventually evolve from a sclerotic stage to a nonindurated stage, and residual hypopigmentation or hyperpigmentation follows. The histologic pattern in patients with morphea is similar to that in patients with progressive systemic sclerosis. Although treatment is nonstandardized, hydroxychloroquine sulfate may be beneficial.

Original languageEnglish (US)
Pages (from-to)1068-1076
Number of pages9
JournalMayo Clinic proceedings
Volume70
Issue number11
DOIs
StatePublished - Jan 1 1995

Fingerprint

Localized Scleroderma
Hypopigmentation
Hydroxychloroquine
Diffuse Scleroderma
Hyperpigmentation
Systemic Scleroderma
Physicians
Skin
Therapeutics

Keywords

  • EMS
  • eosinophilia-myalgia syndrome
  • IL
  • interleukin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Classification of Morphea (Localized Scleroderma). / Peterson, Lynne; Nelson, Audrey M.; Su, W. P.Daniel.

In: Mayo Clinic proceedings, Vol. 70, No. 11, 01.01.1995, p. 1068-1076.

Research output: Contribution to journalArticle

Peterson, Lynne ; Nelson, Audrey M. ; Su, W. P.Daniel. / Classification of Morphea (Localized Scleroderma). In: Mayo Clinic proceedings. 1995 ; Vol. 70, No. 11. pp. 1068-1076.
@article{87994d0cc9904cf2ae2e8e801f1b19e3,
title = "Classification of Morphea (Localized Scleroderma)",
abstract = "To classify and describe morphea (localized scleroderma). A review of morphea and its subtypes is presented. The current classification of morphea is incomplete and confusing. As knowledge of the spectrum of disease continues to evolve, the controversy and confusing nature of its multiple subtypes present a challenge for the physician who encounters a patient with this condition. Thus, we propose that morphea be classified into the following five groups: plaque, generalized, bullous, linear, and deep. This classification, based on clinical morphologic findings, will simplify the diagnostic and therapeutic approach. Morphea represents a wide variety of clinical entities that seem to be on the opposite end of the scleroderma spectrum from systemic sclerosis. The cutaneous lesions eventually evolve from a sclerotic stage to a nonindurated stage, and residual hypopigmentation or hyperpigmentation follows. The histologic pattern in patients with morphea is similar to that in patients with progressive systemic sclerosis. Although treatment is nonstandardized, hydroxychloroquine sulfate may be beneficial.",
keywords = "EMS, eosinophilia-myalgia syndrome, IL, interleukin",
author = "Lynne Peterson and Nelson, {Audrey M.} and Su, {W. P.Daniel}",
year = "1995",
month = "1",
day = "1",
doi = "10.4065/70.11.1068",
language = "English (US)",
volume = "70",
pages = "1068--1076",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Classification of Morphea (Localized Scleroderma)

AU - Peterson, Lynne

AU - Nelson, Audrey M.

AU - Su, W. P.Daniel

PY - 1995/1/1

Y1 - 1995/1/1

N2 - To classify and describe morphea (localized scleroderma). A review of morphea and its subtypes is presented. The current classification of morphea is incomplete and confusing. As knowledge of the spectrum of disease continues to evolve, the controversy and confusing nature of its multiple subtypes present a challenge for the physician who encounters a patient with this condition. Thus, we propose that morphea be classified into the following five groups: plaque, generalized, bullous, linear, and deep. This classification, based on clinical morphologic findings, will simplify the diagnostic and therapeutic approach. Morphea represents a wide variety of clinical entities that seem to be on the opposite end of the scleroderma spectrum from systemic sclerosis. The cutaneous lesions eventually evolve from a sclerotic stage to a nonindurated stage, and residual hypopigmentation or hyperpigmentation follows. The histologic pattern in patients with morphea is similar to that in patients with progressive systemic sclerosis. Although treatment is nonstandardized, hydroxychloroquine sulfate may be beneficial.

AB - To classify and describe morphea (localized scleroderma). A review of morphea and its subtypes is presented. The current classification of morphea is incomplete and confusing. As knowledge of the spectrum of disease continues to evolve, the controversy and confusing nature of its multiple subtypes present a challenge for the physician who encounters a patient with this condition. Thus, we propose that morphea be classified into the following five groups: plaque, generalized, bullous, linear, and deep. This classification, based on clinical morphologic findings, will simplify the diagnostic and therapeutic approach. Morphea represents a wide variety of clinical entities that seem to be on the opposite end of the scleroderma spectrum from systemic sclerosis. The cutaneous lesions eventually evolve from a sclerotic stage to a nonindurated stage, and residual hypopigmentation or hyperpigmentation follows. The histologic pattern in patients with morphea is similar to that in patients with progressive systemic sclerosis. Although treatment is nonstandardized, hydroxychloroquine sulfate may be beneficial.

KW - EMS

KW - eosinophilia-myalgia syndrome

KW - IL

KW - interleukin

UR - http://www.scopus.com/inward/record.url?scp=0028788272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028788272&partnerID=8YFLogxK

U2 - 10.4065/70.11.1068

DO - 10.4065/70.11.1068

M3 - Article

C2 - 7475336

AN - SCOPUS:0028788272

VL - 70

SP - 1068

EP - 1076

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -